Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, safety and tolerability of tofacitinib for juvenile idiopathic arthritis
2015-001438-46Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) comparing Tofacitinib with Placebo (2 arms). Primary endpoint: Primary disease flare endpoint. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2015-001438-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001438-46.